Global disparities in access to hepatitis C medicines before and during the early phase of the COVID-19 pandemic: an ARIMA-based interrupted time series analysis
Background The introduction of direct-acting antivirals (DAAs) has allowed countries to reduce the health and economic burden of hepatitis C virus (HCV). However, access to DAAs remains expensive and limited in many countries globally due to wide disparities in HCV drug pricing. We assessed how glob...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-06-01
|
| Series: | BMJ Public Health |
| Online Access: | https://bmjpublichealth.bmj.com/content/3/1/e001340.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|